TransformativeMed Offering a COVID-19/Core Work Manager App to Seattle-Area Hospitals/Medical Centers Free of Charge During the COVID-19 Outbreak

COVID-19/CORES is already being used at UW Medicine, which includes the University of Washington Medical Center and Harborview Medical Center. The application is being implemented at another Seattle-based health system now, and it will be deployed at other hospitals and health systems in the U.S. in the next few days.

“With current resource limitations, it is imperative that we have technology solutions that help us track potential COVID-19 cases as well as monitor those that are already in the system,” said Erik Van Eaton, MD, a faculty member at the University of Washington who specializes in trauma and surgical critical care. “This application is critical for our tracking of suspected and confirmed cases. It provides better processes, workflows and an improved communication platform for both internal care team communications as well as data delivery to the health department. We have definitely seen an increased ability to organize our treatment of patients.”

The existing CORES app provides specialty-specific workflow and content, integrates workflows and coordinates patient handoffs. A development team at TransformativeMed has worked around the clock to make program updates customized for COVID-19.

“All of us at TransformativeMed are committed to combatting this deadly virus, and our staff has been working tirelessly to modify and implement our CORES application for COVID-19,” said Doug Cusick, CEO. “We are closely monitoring how the end users are working with the app and making modifications and adjustments where necessary so we can continue improving care delivery and monitoring virus cases in these institutions.”

In the next few days, TransformativeMed plans to make its COVID-19/CORES application free of charge during the coronavirus outbreak to other hospitals and health systems. For more information, please visit transformativemed.com.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”